All In Biotech

Drug Trial Radar · NCT00685477

Dose Response of Intravenous Sincalide(CCK-8) for Gallbladder Emptying

Dose Response of Intravenous Sincalide (CCK-8) for Gallbladder Emptying

Last checked: Nov 19, 2026Latest source record: Feb 17, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

60

Actual

Start

May 2008

Primary completion

May 2009

Study completion Jul 2009

Sponsor

Lead sponsor
Temple UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Johns Hopkins University; Penn State University; Memorial Health University Medical Center
First posted
May 28, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Crossover
Masking
Single (participant)
Primary purpose
Diagnostic
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a clinical research study to establish normal values for the infusion of a synthetic form of the hormone cholecystokinin(CCK-8) for gallbladder emptying. Cholecystokinin is released from the small bowel to stimulate the pancreas and gallbladder to help digest and absorb food. Some people have gallbladder problems and need to be tested with the synthetic cholecystokinin ( Kinevac®, Bracco Diagnostics, Inc.). The aim of this study is to find out how differing amounts and intravenous infusion times of CCK-8 affect gallbladder emptying. The findings in normal subjects will be used to establish normal values that can then be compared with patients with suspected gallbladder disease.

Conditions

  • Healthy

Interventions

  • Experimental Sequence ABCDrug

    Drug will be given over 15 minutes, followed by infusion over 30 minutes, followed by infusion over 60 minutes

  • Experimental Sequence ACBDrug

    Drug infused over 15 minutes, followed by infusion over 60 minutes, followed by infusion over 30 minutes

  • Experimental Sequence BACDrug

    Drug will be given over 30 min infusion, followed by 15 minute infusion, followed by 60 minute infusion

  • Experimental Sequence BCADrug

    Drug will be given over 30 min infusion, followed by 60 minute infusion, followed by 15 minute infusion

  • Experimental Sequence CABDrug

    Drug will be given over 60 min infusion, followed by 15 minute infusion, followed by 30 minute infusion

  • Experimental Sequence CBADrug

    Drug will be given over 60 min infusion, followed by 30 minute infusion, followed by 15 minute infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Coefficient of Variation (CV) for Gallbladder Ejection Fraction (GBEF) for Each Infusion MethodTime frame: 15, 30, 45, and 60 minutes post drug infusion

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Temple University Hospital

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.